Clinical Overview
Ranitidine Injection (25mg/ml) is an intravenous histamine H2-receptor antagonist on the WHO Model List of Essential Medicines. It competitively and reversibly binds to histamine H2 receptors on gastric parietal cells, suppressing basal, nocturnal, and secretagogue-stimulated gastric acid and pepsin secretion. Indicated for hospital treatment of pathological hypersecretory states, active peptic ulcer hemorrhage, stress ulcer prophylaxis in critically ill patients, and prevention of acid aspiration during anesthesia.
Active Pharmaceutical Ingredients
Verified Clinical References
Usage Guidelines
Administer intravenously by slow IV injection (dilute to 20 mL with 0.9% NaCl and inject over at least 5 minutes) or intermittent IV infusion (dilute 50 mg in 100 mL compatible IV fluid and infuse over 15-20 minutes every 6 to 8 hours). Rapid IV injection may cause transient bradycardia.
General Administration Advice: Adhere strictly to the prescribed dosage, frequency, and treatment course. For oral medications, swallow with sufficient water. Never stop antibiotics, psychiatric medications, or antihypertensives abruptly without clinical direction.
Possible Side Effects
Common: Transient injection site irritation, headache, dizziness, constipation, diarrhea. Rare/Severe: Bradycardia, AV block, asystole (with rapid IV push), thrombocytopenia, leukopenia, and acute pancreatitis.
*Note: Individual physiological responses vary. While many patients experience few or no side effects, notify your treating physician if adverse reactions persist or if hypersensitivity (angioedema, skin rash, dyspnea) occurs.
Precautions & Warnings
Administer IV slowly over >5 minutes to avoid cardiac dysrhythmias. Adjust dosage in moderate to severe renal impairment (CrCl < 50 mL/min). Ensure product batch meets regulatory NDMA nitrosamine purity standards.
Medical Disclaimer: Statutory Clinical Disclaimer: The information provided is for educational and price-transparency purposes only and does not constitute medical advice, clinical diagnosis, or gastrointestinal treatment recommendations. Always consult a registered gastroenterologist or qualified medical practitioner before initiating, altering, or discontinuing any gastrointestinal medication or digestive therapy.
Ranitidine Tablets 150 mg
Ranitidine Tablets (150mg, 300mg) and Syrup (75mg/5ml) is a selective, competitive histamine H2-receptor antagonist on the WHO Model List of Essential Medicines. It suppresses basal and nocturnal gastric acid secretion by over 70% and diminishes acid response to food and pentagastrin. Indicated for short-term treatment and maintenance of active duodenal ulcers, benign gastric ulcers, GERD, acid indigestion, and Zollinger-Ellison syndrome.
Ranitidine Tablets 300 mg
Ranitidine Tablets (150mg, 300mg) and Syrup (75mg/5ml) is a selective, competitive histamine H2-receptor antagonist on the WHO Model List of Essential Medicines. It suppresses basal and nocturnal gastric acid secretion by over 70% and diminishes acid response to food and pentagastrin. Indicated for short-term treatment and maintenance of active duodenal ulcers, benign gastric ulcers, GERD, acid indigestion, and Zollinger-Ellison syndrome.
Ranitidine 150mg + Domperidone 10mg Tablets
Ranitidine (150mg) and Domperidone (10mg) Tablets combines an H2-receptor antagonist with a peripheral prokinetic dopamine antagonist. Ranitidine reduces gastric acid volume and acidity, while domperidone accelerates gastric emptying and reinforces lower esophageal sphincter tone. Indicated for GERD, dyspepsia, hyperacidity, and heartburn accompanied by nausea or gastric stasis.
Ranitidine Syrup 75 mg per 5ml
Ranitidine Tablets (150mg, 300mg) and Syrup (75mg/5ml) is a selective, competitive histamine H2-receptor antagonist on the WHO Model List of Essential Medicines. It suppresses basal and nocturnal gastric acid secretion by over 70% and diminishes acid response to food and pentagastrin. Indicated for short-term treatment and maintenance of active duodenal ulcers, benign gastric ulcers, GERD, acid indigestion, and Zollinger-Ellison syndrome.